Immunological evaluation of vaccination with pre-designated peptides frequently selected as vaccine candidates in an individualized peptide vaccination regimen

  • Authors:
    • Kazuo Mochizuki
    • Yuji Sato
    • Naotake Tsuda
    • Hiroki Shomura
    • Masaru Sakamoto
    • Kimio Matsuura
    • Kimio Ushijima
    • Yoshiaki Maeda
    • Kazuko Katagiri
    • Akira Yamada
    • Satoru Todo
    • Toshiharu Kamura
    • Mamoru Harada
    • Kyogo Itoh
  • View Affiliations

  • Published online on: July 1, 2004     https://doi.org/10.3892/ijo.25.1.121
  • Pages: 121-131
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

We previously conducted a trial of an ‘individualized’ regimen, in which cancer patients were vaccinated with peptides after the confirmation of pre-existing peptide-specific cytotoxic T lymphocyte (CTL) precursors. In this study, we performed a new trial of ‘pre-designated’ regimen, in which cancer patients were vaccinated with peptides that were frequently selected as vaccine candidates in the preceding individualized regimen. Eighteen cancer patients (10 with uterine cervical cancer and 8 with gastric cancer) were enrolled in the new regimen. The pre-designated regimen was well tolerated by all patients. Although peptide-specific CTL precursors and humoral responses increased in the majority of patients with the pre-designated regimen, neither of the responses correlated with clinical outcome. Three patients had long stable disease, and their pre-vaccination peripheral blood mononuclear cells contained peptide-specific CTL precursors reactive to more than 2 of 4 peptides. With the pre-designated regimen, the levels of pre-existing immunoglobulin G reactive to non-vaccinated peptides decreased in 5 of 15 patients with progressive disease, and their time to progression was very short, whereas such a decrease was rarely observed in the preceding individualized regimen. These results suggest that the pre-designated regimen can elicit a primary immune response, but may incidentally suppress pre-existing immune responses.

Related Articles

Journal Cover

July 2004
Volume 25 Issue 1

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Mochizuki K, Sato Y, Tsuda N, Shomura H, Sakamoto M, Matsuura K, Ushijima K, Maeda Y, Katagiri K, Yamada A, Yamada A, et al: Immunological evaluation of vaccination with pre-designated peptides frequently selected as vaccine candidates in an individualized peptide vaccination regimen. Int J Oncol 25: 121-131, 2004
APA
Mochizuki, K., Sato, Y., Tsuda, N., Shomura, H., Sakamoto, M., Matsuura, K. ... Itoh, K. (2004). Immunological evaluation of vaccination with pre-designated peptides frequently selected as vaccine candidates in an individualized peptide vaccination regimen. International Journal of Oncology, 25, 121-131. https://doi.org/10.3892/ijo.25.1.121
MLA
Mochizuki, K., Sato, Y., Tsuda, N., Shomura, H., Sakamoto, M., Matsuura, K., Ushijima, K., Maeda, Y., Katagiri, K., Yamada, A., Todo, S., Kamura, T., Harada, M., Itoh, K."Immunological evaluation of vaccination with pre-designated peptides frequently selected as vaccine candidates in an individualized peptide vaccination regimen". International Journal of Oncology 25.1 (2004): 121-131.
Chicago
Mochizuki, K., Sato, Y., Tsuda, N., Shomura, H., Sakamoto, M., Matsuura, K., Ushijima, K., Maeda, Y., Katagiri, K., Yamada, A., Todo, S., Kamura, T., Harada, M., Itoh, K."Immunological evaluation of vaccination with pre-designated peptides frequently selected as vaccine candidates in an individualized peptide vaccination regimen". International Journal of Oncology 25, no. 1 (2004): 121-131. https://doi.org/10.3892/ijo.25.1.121